A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Clinical trial NCT07546500 · RECRUITING
Trial details
- NCT number
- NCT07546500
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-17
- Primary completion
- 2028-05-31
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.